Monoamine oxidase inhibitors, their structural analogues, and neuroprotection
Bernard N Sowa1, Andrew Holt, Kathryn G Todd
1Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada T6G 2R7.
Abstract:
Monoamine oxidase (MAO) inhibitors have been used for many years in the treatment of psychiatric and neurological disorders. More recently, some of these drugs and their analogues have been shown to have neuroprotective and neurorescue effects in several models of neurologic insult, including in vitro and in vivo models of cerebral ischemia. This review will discuss current evidence regarding these aspects of l-deprenyl, tranylcypromine, phenelzine, and some structurally related drugs.
Related Concept Videos
Drugs Affecting Neurotransmitter Synthesis
Antidepressant Drugs: MAOIs and Other Agents
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Drugs Affecting Neurotransmitter Release or Uptake
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...

